deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT04014335

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

An Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Subjects With Primary IgA Nephropathy

Sponsor: Ionis Pharmaceuticals, Inc.

Conditions Primary IgA Nephropathy
Interventions IONIS-FB-LRx
Updated 21 times since 2019 Last updated: Jan 17, 2025 Started: Dec 4, 2019 Primary completion: Feb 8, 2024 Completion: Apr 11, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04014335, this PHASE2 trial focuses on Primary IgA Nephropathy and remains completed. Sponsored by Ionis Pharmaceuticals, Inc., it has been updated 21 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jul 2022 · 8 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshot~Sep 2023 – ~Mar 2024 · 6 months · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – present · 17 months · monthly snapshot

Change History

21 versions recorded

  1. Feb 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 16 earlier versions

  1. Mar 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2022 — Sep 2023 [monthly]

    Recruiting PHASE2

  4. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  5. Nov 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

  6. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  8. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  10. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  11. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  12. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  13. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  14. Oct 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE2

  15. Sep 2019 — Oct 2019 [monthly]

    Not Yet Recruiting PHASE2

  16. Aug 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ionis Pharmaceuticals, Inc.
Data source: Ionis Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations